Biodesix Statistics

Total Valuation

Biodesix has a market cap or net worth of $101.12 million. The enterprise value is $158.93 million.

Market Cap	101.12M
Enterprise Value	158.93M

Important Dates

The next confirmed earnings date is Monday, May 4, 2026, after market close.

Earnings Date	May 4, 2026
Ex-Dividend Date	n/a

Share Statistics

Biodesix has 10.11 million shares outstanding. The number of shares has increased by 16.71% in one year.

Current Share Class	10.11M
Shares Outstanding	10.11M
Shares Change (YoY)	+16.71%
Shares Change (QoQ)	+7.53%
Owned by Insiders (%)	38.72%
Owned by Institutions (%)	22.32%
Float	6.10M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.16
Forward PS	0.93
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1.80
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.86

Current Ratio	1.86
Quick Ratio	1.61
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-3.60

Financial Efficiency

Return on equity (ROE) is -383.09% and return on invested capital (ROIC) is -22.33%.

Return on Equity (ROE)	-383.09%
Return on Assets (ROA)	-18.79%
Return on Invested Capital (ROIC)	-22.33%
Return on Capital Employed (ROCE)	-39.64%
Weighted Average Cost of Capital (WACC)	7.69%
Revenue Per Employee	$264,967
Profits Per Employee	-$105,584
Employee Count	334
Asset Turnover	0.96
Inventory Turnover	14.54

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -6.22% in the last 52 weeks. The beta is 0.57, so Biodesix's price volatility has been lower than the market average.

Beta (5Y)	0.57
52-Week Price Change	-6.22%
50-Day Moving Average	14.44
200-Day Moving Average	9.58
Relative Strength Index (RSI)	31.60
Average Volume (20 Days)	54,484

Short Selling Information

The latest short interest is 174,016, so 1.72% of the outstanding shares have been sold short.

Short Interest	174,016
Short Previous Month	181,818
Short % of Shares Out	1.72%
Short % of Float	2.85%
Short Ratio (days to cover)	2.55

Income Statement

In the last 12 months, Biodesix had revenue of $88.50 million and -$35.27 million in losses. Loss per share was -$4.67.

Revenue	88.50M
Gross Profit	71.78M
Operating Income	-27.77M
Pretax Income	-35.27M
Net Income	-35.27M
EBITDA	-22.10M
EBIT	-27.77M
Loss Per Share	-$4.67

Full Income Statement

Balance Sheet

The company has $18.99 million in cash and $75.03 million in debt, giving a net cash position of -$56.04 million or -$5.54 per share.

Cash & Cash Equivalents	18.99M
Total Debt	75.03M
Net Cash	-56.04M
Net Cash Per Share	-$5.54
Equity (Book Value)	-2.47M
Book Value Per Share	-0.30
Working Capital	15.08M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$23.27 million and capital expenditures -$259,000, giving a free cash flow of -$23.53 million.

Operating Cash Flow	-23.27M
Capital Expenditures	-259,000
Depreciation & Amortization	5.67M
Net Borrowing	9.98M
Free Cash Flow	-23.53M
FCF Per Share	-$2.33

Full Cash Flow Statement

Margins

Gross margin is 81.11%, with operating and profit margins of -31.37% and -39.85%.

Gross Margin	81.11%
Operating Margin	-31.37%
Pretax Margin	-39.85%
Profit Margin	-39.85%
EBITDA Margin	-24.97%
EBIT Margin	-31.37%
FCF Margin	n/a

Dividends & Yields

Biodesix does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.71%
Shareholder Yield	-16.71%
Earnings Yield	-34.27%
FCF Yield	-22.87%

Analyst Forecast

The average price target for Biodesix is $32.50, which is 224.84% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$32.50
Price Target Difference	224.84%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on September 15, 2025. It was a reverse split with a ratio of 1:20.

Last Split Date	Sep 15, 2025
Split Type	Reverse
Split Ratio	1:20

Scores

Biodesix has an Altman Z-Score of -7.28 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.28
Piotroski F-Score	3